OXULAR
Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs.
OXULAR
Industry:
Health Care Medical Therapeutics
Founded:
2014-01-01
Address:
Oxford, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.oxular.com
Total Employee:
11+
Status:
Active
Contact:
+44 (0)1865 636200
Total Funding:
76.71 M USD
Technology used in webpage:
SPF LetsEncrypt Apache Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Bizland StratLogic DNS
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
SONE Health
SONE Health is an Italian company born from an intuition of its founders about the mechanical functionality of the classic stethoscope!
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Sapiens Steering Brain Stimulation
Sapiens is a medical device company that delivers solutions for deep brain stimulation therapy.
PlusDental
PlusDental is a Berlin-based Health-Tech Startup in the area of digital dentistry.
Current Advisors List
Board_member
2016-07-01
Board_member
2021-03-01
Current Employees Featured
Tom Cavanagh CEO & Co-Founder @ Oxular
CEO & Co-Founder
Ronald Yamamoto Chief Scientific Officer @ Oxular
Chief Scientific Officer
2016-02-01
Founder
Investors List
IP Group
IP Group investment in Series B - Oxular
Neomed Management
Neomed Management investment in Series B - Oxular
V-Bio Ventures
V-Bio Ventures investment in Series B - Oxular
Forbion Capital Partners
Forbion Capital Partners investment in Series B - Oxular
V-Bio Ventures
V-Bio Ventures investment in Series A - Oxular
Imperial Innovations
Imperial Innovations investment in Series A - Oxular
Consort Medical
Consort Medical investment in Series A - Oxular
Imperial Innovations
Imperial Innovations investment in Series A - Oxular
Official Site Inspections
http://www.oxular.com
- Host name: aeedc42b70c898c66.awsglobalaccelerator.com
- IP address: 3.33.139.32
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Oxular"
About Us – Oxular
V-Bio Ventures finds, builds, and finances innovative life sciences companies. The company invests throughout Europe in start-up and early-stage companies with high growth potential as …See details»
Oxular - Crunchbase Company Profile & Funding
Organization. Oxular . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the …See details»
Oxular Company Profile 2025: Valuation, Investors, Acquisition
Oxular General Information Description. Operator of a retinal therapeutics company intended to offer retinal disease treatment. The company provides tissue-specific delivery of potent drug …See details»
Oxular - LinkedIn
Oxular’s product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema, as well as rare and orphan indications, including treatments for ocular ...See details»
Regeneron snaps up eye company, snaring science but not staff
2 days ago Regeneron has scooped up Oxular, a retinal-disease-focused company based in the U.K., closing the deal at the very end of 2024. Word of the acquisition was first shared by …See details»
Oxular - Company Profile - Tracxn
Nov 16, 2024 Oxular ranks 22nd among 296 active competitors. 100 of its competitors are funded while 78 have exited. Overall, Oxular and its competitors have raised over $6B in …See details»
Oxular Company Profile - Office Locations, Competitors, Revenue …
Oxular is an ophthalmic company developing drug and device combination treatments for retinal disease. Its product development pipeline includes treatments for such diseases as age …See details»
Oxular - Leadership Team - The Org
The Leadership Team at Oxular drives the strategic vision and operational execution of the company’s innovative therapies for retinal diseases. Comprising experts in medicine, science, …See details»
Oxular (fka Precision Ocular) - VentureRadar
" Oxular is a leading, clinical-stage retinal therapeutics company that is developing technology to transform the treatment of retinal disease. There is significant need for new, broader-acting …See details»
Oxular - The Org
Oxular is developing disruptive treatments for retinal diseases. Oxular’s sustained-release formulations are engineered to last up to one year following single administration and perform …See details»
Oxular Company Profile: Overview and Full News Analysis
Oxular is dedicated to advancing the field of ophthalmology through cutting-edge technology and research. One of the key products offered by Oxular is a revolutionary retinal imaging system …See details»
Regeneron builds in eye disease tech with Oxular takeover
2 days ago Oxular's lead programme is OXU-001, a formulation of the corticosteroid dexamethasone that uses both of the company's technology platforms and which recently …See details»
Oxular CEO and Key Executive Team | Craft.co
Oxular's Director, Chief Executive Officer is Thomas Cavanagh. Other executives include David Fellows, Chairman; Dina Chaya, Director and 7 others. See the full leadership team at Craft.See details»
Regeneron eyes novel drug delivery with Oxular buy
2 days ago Regeneron acquires UK-based Oxular, adding ocular delivery technology and Phase II therapy OXU-001 for diabetic macular edema to its pipeline. The move strengthens …See details»
Oxular - Overview, News & Similar companies | ZoomInfo.com
Oct 3, 2023 Oxular Limited Announces Acceptance of IND for Suprachoroidal OXU-001 for the Treatment of Diabetic Macular Edema OXFORD, United Kingdom--(BUSINESS WIRE)- …See details»
Our technology – Oxular
Oxular’s technologies were developed together to find solutions that would solve significant remaining unmet challenges in retinal care. Together, these systems will transform the …See details»
Regeneron expands in eye care with Oxular deal (REGN:NASDAQ)
2 days ago Regeneron Pharmaceuticals (REGN) expands its focus on eye care with the acquisition of Oxular, a U.K.-based biotech developing retinal treatments. Read more here.See details»
Oxular - Rosetta Capital
Oxular is developing a minimally invasive administration device for delivery of therapeutics to the suprachoroidal space of the eye and sustained release therapeutics for retinal diseases. …See details»
About Us - Oxular
V-Bio Ventures finds, builds, and finances innovative life sciences companies. The company invests throughout Europe in start-up and early-stage companies with high growth potential as …See details»
Partnering – Oxular
Oxular is actively partnering with industry peers to utilize the potential of our technology across multiple modalities and indications. Creating value through relationships. Oxular’s technologies …See details»